OLFM4 / GW112 Antikörper

Sino Biological Inc. liefert OLFM4 / GW112 Antikörper mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über OLFM4 / GW112 Antikörper lesen Sie bitte: http://www.sinobiological.com/OLFM4-GW112-Antibody-g-10055.html

Produkt-Information von OLFM4 / GW112 Antikörper

Usage Guide von OLFM4 / GW112 Antikörper

Specificity	Human OLFM4 / GW112
Flow Cytometry	Flow cytometric analysis of Human OLFM4 expression in DU145 cells. The cells were treated according to manufacturer's manual (BD Pharmingen™ Cat. No. 554714), and stained with Purified Mouse anti-OLFM4 (11639-MM12), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. Flow cytometry was performed on a BD FACSCalibur flow cytometry system Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.
Direct ELISA	This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human OLFM4.
Storage	This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Verwandte Produkte & Themen von OLFM4 / GW112 Antikörper

Cancer>>Cancer Biomarkers>>OLFM4/GW112

Hintergrund von OLFM4 / GW112 Antikörper

Olfactomedin-4, also known as G-CSF-stimulated clone 1 protein, Antiapoptotic protein GW112, and OLFM4, is a secreted protein which contains oneolfactomedin-like domain. OLFM4 is expressed during myeloid lineage development. It is strongly expressed in the prostate, small intestine and colon and moderately expressed in the bone marrow and stomach. OLFM4 is highly expressed in pancreatic cancer tissues and shows an elevated expression level during the early S phase of the cell cycle. It is also expressed at high levels in stomach cancer and colon cancer tissues. Inhibition of ROS or the ERK pathway remarkably decreased G-CSF-induced OLFM4 expression. OLFM4 is an antiapoptotic factor that promotes tumor growth. OLFM4 promotes proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. OLFM4 also facilitates cell adhesion. Induction of OLFM4 in cancer cells was reported to have a novel antiapoptotic action via binding to the potent apoptosis inducer GRIM-19. The human OLFM4 is also thought to be a useful marker for early myeloid development.

References

1. Zhang J., et al., 2002, Gene 283: 83-93.
2. Zhang X., et al., 2004, Cancer Res. 64: 2474-2481.
3. Kobayashi D., 2007, et al., Cancer Sci. 98: 334-340.
4. Kobayashi, D.et al., 2007, Cancer Sci. 98 (3): 334-40.
5. van der Flier, L.G. et al., 2009, Gastroenterology. 137 (1): 15-7.

Primary Antibody Products